1531651816705884170

In addition to our lead NK cell therapy candidate, GDA-201, we are opening new frontiers in cancer immunotherapy with our product candidates, GDA-301/401/501/601 for hematologic cancers and solid tumors. Learn more here: https://t.co/5HaGv5EiyC https://t.co/uIWU3iGpox

Send us a message